8-K: BeyondSpring Reports 2024 Year-End Financial Results and Highlights Clinical and Strategic Milestones

BeyondSpring Inc. announced its 2024 year-end financial results, highlighting clinical progress for Plinabulin and strategic advancements for SEED Therapeutics.

Summary

• BeyondSpring Inc. reported its financial results for the year ended December 31, 2024.
• Plinabulin demonstrated a statistically significant survival benefit in patients with secondand third-line non-small cell lung cancer (NSCLC) (EGFR wild-type).
• Phase 3 data for Plinabulin was published in The Lancet Respiratory Medicine.
• BeyondSpring is preparing for submission to the Chinese National Medical Products Administration (NMPA).
• An ongoing Phase 2 study showed that Plinabulin, in combination with a PD-1 inhibitor and docetaxel, produced promising efficacy in patients with metastatic NSCLC who had progressed on prior PD-1/PD-L1 inhibitors.
• SEED Therapeutics secured a strategic research collaboration with Eisai Co., Ltd., potentially receiving up to $1.5 billion in milestone payments and royalties.
• SEED's lead oncology asset, RBM39 degrader, received Rare Pediatric Disease and Orphan Drug Designations by the FDA.
• R&D expenses were $2.6 million in 2024, compared to $7.3 million in 2023.
• G&A expenses were $6.1 million in 2024, compared to $7.8 million in 2023.
• Net loss was $8.9 million in 2024, compared to $14.0 million in 2023.
• Cash, cash equivalents, and short-term investments were $2.9 million as of December 31, 2024.

Sentiment

Score: 7

Explanation: The document presents a mix of positive clinical and strategic developments alongside financial losses. The progress in clinical trials and partnerships is encouraging, but the limited cash position and ongoing losses temper the overall outlook.

Positives

• Plinabulin demonstrated a statistically significant survival benefit in patients with secondand third-line NSCLC (EGFR wild-type).
• SEED Therapeutics secured a strategic research collaboration with Eisai, potentially receiving up to $1.5 billion.
• SEED's RBM39 degrader received Rare Pediatric Disease and Orphan Drug Designations from the FDA.
• R&D and G&A expenses decreased year-over-year.
• Net loss decreased year-over-year.

Negatives

• The company had a net loss of $8.9 million from continuing operations.
• Cash, cash equivalents, and short-term investments were $2.9 million as of December 31, 2024.

Risks

• The company's future operations are subject to difficulties in raising the anticipated amount needed to finance them.
• Unexpected results of clinical trials could impact the company.
• Delays or denial in the regulatory approval process could impact the company.
• Increased competition in the market could impact the company.
• The company's ability to meet Nasdaq's continued listing requirements is a risk.

Future Outlook

BeyondSpring and SEED are positioned to drive transformative advancements in oncology and TPD in 2025, with key milestones expected for Plinabulin and SEED's RBM39 degrader.

Management Comments

• '2024 was a pivotal year for BeyondSpring, with significant clinical progress for our first-in-class agent Plinabulin and strategic advancements for SEED Therapeutics (SEED), which BeyondSpring co-founded and owns an equity stake in.'
• 'We believe these developments create value benefiting all stakeholders,' said Dr. Lan Huang, Co-Founder, Chairman, and CEO of BeyondSpring.

Industry Context

The collaboration between SEED Therapeutics and Eisai highlights the increasing interest in targeted protein degradation as a therapeutic approach in oncology and neurodegenerative diseases, reflecting a broader industry trend towards innovative drug development strategies.

Comparison to Industry Standards

• Plinabulin's statistically significant survival benefit in 2L/3L NSCLC EGFR wild-type is notable, as no new therapies have been approved in this setting in over a decade.
• The PD-1 and PD-L1 antibody annual sales have exceeded $50 billion, with most sales coming from lung cancer, highlighting the potential market for Plinabulin to address acquired resistance to checkpoint inhibitors.
• SEED's collaboration with Eisai, potentially worth up to $1.5 billion, is comparable to other major pharma partnerships in the TPD space, such as those between Arvinas and Pfizer.
• The Rare Pediatric Disease and Orphan Drug Designations granted to SEED's RBM39 degrader ST-01156 are similar to those received by other companies developing novel therapies for rare cancers, such as Kura Oncology for its farnesyltransferase inhibitor tipifarnib.

Stakeholder Impact

• Shareholders may benefit from the potential regulatory approvals and commercialization of Plinabulin.
• Employees may benefit from the company's growth and expansion.
• Patients may benefit from the development of new cancer therapies.
• The company's financial performance and strategic partnerships may impact suppliers and creditors.

Next Steps

• BeyondSpring plans to submit Plinabulin for regulatory approval to the Chinese NMPA.
• BeyondSpring will continue advancing Plinabulin's potential as a next-generation immuno-oncology agent.
• SEED Therapeutics expects to file an IND for its RBM39 degrader in mid-2025 and begin patient enrollment in the second half of 2025.
• SEED Therapeutics expects its Tau degrader to achieve in vivo efficacy in the second half of 2025.

Key Dates

Keywords

Plinabulin, SEED Therapeutics, NSCLC, RBM39 degrader, Eisai, Financial Results, Clinical Trials, Oncology, FDA, BYSI